About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Malignancy Meta Analysis for BRL49653 | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT01195259

Malignancy Meta Analysis for BRL49653

Observational analyses of data from population registeries have suggested that metformin may be associated with a decreased prevalence of malignancy. The ADOPT and RECORD studies both contain groups o...

Lead sponsor: GlaxoSmithKline•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

GlaxoSmithKline

The objective of this meta-analysis is to compare the incidence of malignancy (excluding non-melanomatous skin cancers) reported as serious adverse events in the ADOPT and RECORD studies between subjects randomly allocated to treatment with metformin with those allocated to rosiglitazone.

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Subjects from ADOPT that are included in this meta-analysis (those in the metformin or rosiglitazone groups) had the dose of their study medication increased to a maximum of 2g (metformin) or 8mg (rosiglitazone) if their fasting plasma glucose was greater than 140mg/dl.
•Subjects from RECORD that are included in this meta-analsyis entered the RECORD study taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride). They were randomly allocated to metformin or rosiglitazone in a 1:1 ration to use as add-on treatment to the background of sulfonylurea. These subjects had the dose of their study medication increased to a maximum of 2.55g (metformin) or 8mg (rosiglitazone) if their HbA1c was greater than 7.0%.

Related studies

RECRUITINGPhase 1

A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

NCT07590193 · Diabetes Mellitus, Type 2

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

NCT06574035 · Diabetes Mellitus, Type 2, Depressive Symptoms, and more

Collection of Human Metabolic Tissues

NCT02861781 · Obesity, Insulin Resistance, and more

Mixed Methods Study of Health-Related Social Needs in African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus

NCT05692388 · Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2, and more

Milk for Diabetes Prevention

NCT06513026 · Lactose Intolerance, Lactose Intolerant, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 28, 2013Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment1

Start dateOct 2009

Last updatedOct 28, 2013

Condition

Diabetes Mellitus, Type 2

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 28, 2013Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions